TY - JOUR T1 - Noise-Assisted MEMD-Based Phase-Connectivity Analysis to Personalize Closed-Loop DBS Therapy in Epilepsy Patients JF - medRxiv DO - 10.1101/19006908 SP - 19006908 AU - Sina Farahmand AU - Tiwalade Sobayo AU - David J. Mogul Y1 - 2019/01/01 UR - http://medrxiv.org/content/early/2019/09/16/19006908.abstract N2 - Deep brain stimulation (DBS) is a treatment that has been explored for controlling seizures in patients with intractable epilepsy. Many clinical and pre-clinical studies using DBS therapy determine stimulation parameters through trial and error. The same stimulation parameters are often applied to the whole cohort, which consequently produces mixed results of responders and non-responders. In this paper, an adaptive non-linear analytical methodology is proposed to extract stimulation frequency and location(s) from endogenous brain dynamics of epilepsy patients, using phase-synchrony and phase-connectivity analysis, as seizures evolve. The proposed analytical method was applied to seizures recorded using depth electrodes implanted in hippocampus and amygdala in three patients. A reduction in phase-synchrony was observed in all patients around seizure onset. However, phase-synchrony started to gradually increase from mid-ictal and achieved its maximum level at seizure termination. This result suggests that hyper-synchronization of the epileptic network may be a crucial mechanism by which the brain naturally terminates seizure. Stimulation frequency and locations that matched the network phase-synchrony at seizure termination were extracted using phase-connectivity analysis. One patient with temporal lobe epilepsy (TLE) had a stimulation frequency ∼15 Hz with the stimulation locations confined to the hippocampus. The other two patients with extra-temporal lobe epilepsy (ETE) had stimulation frequency ∼90 Hz with at least one stimulation location outside of hippocampus. These results suggest that DBS parameters should vary based on the patient’s underlying pathology. The proposed methodology provides an algorithm for tuning DBS parameters for individual patients in an effort to increase the clinical efficacy of the therapy.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialWe used clinical data that were made public by Mayo Clinic in IEEG portal. The reference for the portal and adopted data is cited in paper. We did not do any clinical study, we only used available data.Funding StatementResearch supported by National Institute of Health, United States, (R01 NS092760) to David Mogul.Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.Not ApplicableAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.Not ApplicableThe data is available and public in IEEG portal created by Mayo Clinic. Reference of the portal and data is cited in the paper. We only used clinical data and we never performed any clinical study. Clinical data was adopted from IEEG portal: https://www.ieeg.org https://www.ieeg.org ER -